Product Description: Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy[1][2][3][4][5].
Applications: Neuroscience-Neuromodulation
Formula: C21H20F5N3O4
References: [1]WHO Drug Information-World Health Organization (WHO)./[2]Jones J, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405./[3]Zhang H, et al. A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: Method validation and application to pharmacokinetic study. Biomed Chromatogr. 2024 Jul;38(7):e5907. /[4]Yu G, et al. Gender difference in the pharmacokinetics and metabolism of VX-548 in rats. Biopharm Drug Dispos. 2024 Apr;45(2):107-114./[5]Qin H, et al. Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain. Eur J Med Chem. 2023 Jun 5;254:115371.
CAS Number: 2649467-58-1
Molecular Weight: 473.39
Compound Purity: 99.91
Research Area: Neurological Disease
Solubility: DMSO : 116.67 mg/mL (ultrasonic)
Target: Sodium Channel
Deutsch
English
